TRAW icon

Traws Pharma

1.49 USD
+0.06
4.2%
At close Updated May 1, 4:00 PM EDT
Pre-market
After hours
1.49
0.00
0%
1 day
4.2%
5 days
20.16%
1 month
-10.24%
3 months
-26.96%
6 months
-37.66%
Year to date
12.03%
1 year
5.67%
5 years
-99.4%
10 years
-99.99%
 

About: Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.

Employees: 7

0
Funds holding %
of 8,128 funds
Analysts bullish %
0
Positive news %
Price charts implemented using Lightweight Charts™